Cargando…

Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study

BACKGROUND: Identification of specific antigens is highly beneficial for early detection, diagnosis, staging, and outcome prediction of cancer. This study aimed to evaluate the expression and prognostic value of CD56 (140 kDa isoform) in IDC. METHODS: Sixty-five patients with IDC who underwent radic...

Descripción completa

Detalles Bibliográficos
Autores principales: Niknam, Kianoush, Safaei, Akbar, Ghaderi, Abbas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pasteur Institute of Iran 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440685/
https://www.ncbi.nlm.nih.gov/pubmed/35372457
http://dx.doi.org/10.52547/ibj.26.3.175
_version_ 1784782406079741952
author Niknam, Kianoush
Safaei, Akbar
Ghaderi, Abbas
author_facet Niknam, Kianoush
Safaei, Akbar
Ghaderi, Abbas
author_sort Niknam, Kianoush
collection PubMed
description BACKGROUND: Identification of specific antigens is highly beneficial for early detection, diagnosis, staging, and outcome prediction of cancer. This study aimed to evaluate the expression and prognostic value of CD56 (140 kDa isoform) in IDC. METHODS: Sixty-five patients with IDC who underwent radical surgery or mastectomy as the primary treatment were included. Proper formalin-fixed and paraffin embedded tissue blocks of the patients were prepared and stained by IHC for CD56 (140 kDa isoform) molecule. Chi-square and fisher exact tests were used to compare the results against the clinicopathologic data of patients. Kaplan-Meier and log-rank test were employed to study the prognostic value of the target antigen. RESULTS: The expression pattern of CD56 was granular and cytoplasmic. There were significant associations between the intensity of CD56 expression in invasive cells and carcinoma in situ (p = 0.005) and normal ducts (p = 0.010). Among all clinicipathologic parameters, there was only a significant association between the expression of ER and CD56 (p = 0.023). Neither OS (p = 0.356) nor DFS (p = 0.976) had significant correlation with CD56 expression. CONCLUSION: Our data indicated that the CD56 marker offers no prognostic value in terms of predicting the OS or DFS for up to eight years after primary surgery. Furthermore, the intensity of its expression is similar between normal, non-invasive, and invasive cells. Considering the generally better outcome of ER+ BC patients than their ER-counterparts, the CD56 marker may be indirectly associated with a more favorable prognosis among IDC patients.
format Online
Article
Text
id pubmed-9440685
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Pasteur Institute of Iran
record_format MEDLINE/PubMed
spelling pubmed-94406852022-09-14 Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study Niknam, Kianoush Safaei, Akbar Ghaderi, Abbas Iran Biomed J Full Length BACKGROUND: Identification of specific antigens is highly beneficial for early detection, diagnosis, staging, and outcome prediction of cancer. This study aimed to evaluate the expression and prognostic value of CD56 (140 kDa isoform) in IDC. METHODS: Sixty-five patients with IDC who underwent radical surgery or mastectomy as the primary treatment were included. Proper formalin-fixed and paraffin embedded tissue blocks of the patients were prepared and stained by IHC for CD56 (140 kDa isoform) molecule. Chi-square and fisher exact tests were used to compare the results against the clinicopathologic data of patients. Kaplan-Meier and log-rank test were employed to study the prognostic value of the target antigen. RESULTS: The expression pattern of CD56 was granular and cytoplasmic. There were significant associations between the intensity of CD56 expression in invasive cells and carcinoma in situ (p = 0.005) and normal ducts (p = 0.010). Among all clinicipathologic parameters, there was only a significant association between the expression of ER and CD56 (p = 0.023). Neither OS (p = 0.356) nor DFS (p = 0.976) had significant correlation with CD56 expression. CONCLUSION: Our data indicated that the CD56 marker offers no prognostic value in terms of predicting the OS or DFS for up to eight years after primary surgery. Furthermore, the intensity of its expression is similar between normal, non-invasive, and invasive cells. Considering the generally better outcome of ER+ BC patients than their ER-counterparts, the CD56 marker may be indirectly associated with a more favorable prognosis among IDC patients. Pasteur Institute of Iran 2022-05 2022-04-03 /pmc/articles/PMC9440685/ /pubmed/35372457 http://dx.doi.org/10.52547/ibj.26.3.175 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Full Length
Niknam, Kianoush
Safaei, Akbar
Ghaderi, Abbas
Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study
title Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study
title_full Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study
title_fullStr Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study
title_full_unstemmed Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study
title_short Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study
title_sort evaluation of the prognostic value of cd56 (140 kda isoform) expression in breast cancer tissues: an eight-year retrospective study
topic Full Length
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440685/
https://www.ncbi.nlm.nih.gov/pubmed/35372457
http://dx.doi.org/10.52547/ibj.26.3.175
work_keys_str_mv AT niknamkianoush evaluationoftheprognosticvalueofcd56140kdaisoformexpressioninbreastcancertissuesaneightyearretrospectivestudy
AT safaeiakbar evaluationoftheprognosticvalueofcd56140kdaisoformexpressioninbreastcancertissuesaneightyearretrospectivestudy
AT ghaderiabbas evaluationoftheprognosticvalueofcd56140kdaisoformexpressioninbreastcancertissuesaneightyearretrospectivestudy